Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction
Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction
复制标题
DOI：
10.1016/j.cca.2013.12.017
复制
发表时间：
2014-02-15
影响因子：
5
通讯作者：
Rousseau, M. F.
中科院分区：
文献类型：
--
作者：
Gruson, D.;Mancini, M.;Rousseau, M. F.
半乳糖凝集素-3（Gal-3）的循环水平是心脏纤维化和重塑的标志物，有助于心力衰竭（HF）患者的风险分层。本研究的目的是确定一种新的自动化Gal-3测定在射血分数降低的HF患者中的分析有效性和临床有效性。我们发现VIDAS（R）Gal-3自动化检测试剂盒与ELISA参考方法之间具有极好的一致性（r = 0.90，p < 0.001），在Bland和Altman图上观察到的平均差异为-1.3 ng/mL。用VIDAS（R）测定法测量的Gal-3水平与NYHA心功能分级显著相关（p < 0.001），NYHA II级患者的平均Gal-3水平为13.8 ng/mL，NYHA III级患者为17.7 ng/mL，NYHA IV级患者为19.6 ng/mL。此外，我们的研究结果表明，用VIDAS（R）检测法测量的Gal-3水平不仅可预测收缩期HF患者的长期心血管死亡，而且还为多标记策略中的利钠肽检测提供了附加价值。因此，我们的数据也支持Gal-3自动检测试剂盒的临床有效性。(C)© 2014 Elsevier B. V.保留所有权利。
Circulating levels of galectin-3 (Gal-3), a marker of cardiac fibrosis and remodeling, contribute to the risk stratification of patients with heart failure (HF). The aim of our study was to determine the analytical validity and clinical validity of a novel automated Gal-3 assay in HF patients with reduced ejection fraction. We showed an excellent agreement between the VIDAS (R) Gal-3 automated assay and the ELISA reference method (r = 0.90, p < 0.001) and a mean difference of -1.3 ng/mL was observed on the Bland and Altman plot. Gal-3 levels measured with the VIDAS (R) assay were significantly related to NYHA functional classes (p < 0.001) and mean Gal-3 levels were 13.8 ng/mL in NYHA II patients, 17.7 ng/mL in NYHA III and 19.6 ng/mL in NYHA IV. Furthermore, our results showed that Gal-3 levels measured with the VIDAS (R) assay were not only predictive of long-term cardiovascular death in patients with systolic HF but have also provided added value to natriuretic peptide testing in multimarker strategies. Therefore, our data are also supporting the clinical validity of the Gal-3 automated assay. (C) 2014 Elsevier B.V. All rights reserved.